Pfizer Inc (PFE) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Pfizer Inc. (PFE) has launched a new Phase 3 trial, officially titled an interventional open label randomized study of PF-08634404 plus chemotherapy versus pembrolizumab plus chemotherapy in adults with advanced or recurrent mismatch repair proficient endometrial cancer. The goal is to see if Pfizer’s new drug can beat the current standard and improve outcomes in a hard to treat group of patients.
The study tests PF-08634404, a biological drug given by IV, in combination with standard chemotherapy and then as maintenance alone. It is compared against Merck’s pembrolizumab, also with chemotherapy and then as maintenance, to find out which mix gives better and more durable control of the cancer.
The trial uses random assignment so each patient has an equal chance of getting either treatment, and both groups are treated in parallel over time. It is open label, so doctors and patients know which drug they receive, and the main purpose is to see if the new Pfizer therapy can treat disease more effectively than today’s leading option.
The study was first submitted on May 5, 2026, marking the official start of the regulatory process and signaling trial set up is underway. The latest update on May 18, 2026 shows the status as not yet recruiting, which means sites are being activated and patient enrollment is expected to follow, with primary and final completion dates to be confirmed as the trial progresses.
For investors, this trial matters because it directly challenges pembrolizumab, a flagship cancer drug from Merck, in a defined and growing endometrial cancer segment. A clear win could support a new revenue stream for Pfizer in immuno oncology, while mixed data or delays could temper enthusiasm, so sentiment will likely track early safety and efficacy signals once recruitment and interim readouts begin.
The study is currently in the start up phase with status updated on ClinicalTrials.gov, and investors can follow future changes and detailed protocol information on the ClinicalTrials portal as the trial moves forward.
To learn more about PFE’s potential, visit the Pfizer Inc drug pipeline page.